Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Transcat Announces Third Quarter Fiscal Year 2022 Conference Call and Webcast


Transcat, Inc. (Nasdaq: TRNS) ("Transcat" or the "Company"), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it will release its third quarter fiscal year 2022 results after the close of financial markets on Tuesday, February 1, 2022.

The Company will host a conference call and webcast to review the financial and operating results for the period and discuss its corporate strategy and outlook. A question-and-answer session will follow.

Third Quarter Fiscal Year 2022 Conference Call

Wednesday, February 2, 2022
11:00 a.m. Eastern Time
Phone: (201) 689-8471
Webcast and accompanying slide presentation: www.transcat.com/investor-relations

A telephonic replay will be available from 2:00 p.m. ET on the day of the teleconference call until Wednesday, February 9, 2022. To listen to the archived call, dial (412) 317-6671 and enter conference ID number 13726586 or access the webcast replay at www.transcat.com/investor-relations, where a transcript will be posted once available.

ABOUT TRANSCAT

Transcat, Inc. is a leading provider of accredited calibration, repair, inspection and laboratory instrument services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device and other FDA-regulated businesses; as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 22 Calibration Service Centers strategically located across the United States, Puerto Rico and Canada, and services at 20 imbedded customer-site locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry.

Transcat also operates as a leading value-added distributor that markets, sells and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise and integrity create a unique and compelling value proposition for its customers.

Transcat's strategy is to leverage the complementary nature of its two operating segments, its comprehensive service capabilities, strong brand, enhanced e-commerce capabilities and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model.

More information about Transcat can be found at: Transcat.com.


These press releases may also interest you

at 00:50
OKX, a leading Web3 technology company, has issued updates for April 25, 2024. OKX Wallet Now Integrated with XION, a User-First ...

at 00:30
Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), is thrilled to announce its continued partnership with the Tourism Authority of Thailand (TAT) for the fourth consecutive year, showcasing the unparalleled beauty...

at 00:30
ENOC Group, a leading integrated global energy player, has appointed the innovative technology loyalty partner, Loyyal, to integrate Access Point, their self-service platform, into the Group's rewards programme. This move will revolutionize the 'YES'...

at 00:05
Systal Technology Solutions, a global managed network, cloud, and security transformation specialist, today announces the opening of its new Network Operations Center (NOC) in Tampa, Florida. This marks the latest milestone in Systal's recent growth...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:01
ATTOM, a leading curator of land, property, and real estate data, today released its first-quarter 2024 U.S. Home Sales Report, which shows that profit margins on median-priced single-family home and condo sales in the United States decreased to 55.3...



News published on and distributed by: